Sittard/Leiden, The Netherlands, November 16, 2007 - DSM Biologics, a business unit of DSM Pharmaceutical Products and Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced a PER.C6® license agreement with Daiichi Sankyo Ltd. (Tokyo Stock Exchange Ticker 4568). This license agreement allows Daiichi Sankyo to use the PER.C6® cell line in their early stage research to identify new antibodies and for the production of preclinical grade material. Financial details were not disclosed.
